Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

A pair of CROs from opposite sides of the Atlantic Ocean are merging to form a global organization. | A pair of CROs from ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The Department of Health and Human Services (HHS) is laying off certain employees that were notified months ago of the ...

Zimmer Biomet inked a $177 million deal to purchase Monogram Technologies, developer of a hands-free robotic surgery system ...

After 45 years at Henry Schein, including more than three decades as its CEO, Stanley Bergman has announced plans to retire ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...